Edition:
United States

Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

4.10USD
26 Sep 2017
Change (% chg)

$-0.03 (-0.73%)
Prev Close
$4.13
Open
$4.12
Day's High
$4.15
Day's Low
$4.05
Volume
485,100
Avg. Vol
1,017,626
52-wk High
$7.49
52-wk Low
$3.20

Chart for

About

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast... (more)

Overall

Beta: 2.12
Market Cap(Mil.): $359.31
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 60.99 15.77
EPS (TTM): -- -- --
ROI: -- 0.23 15.19
ROE: -- 2.45 13.80

'Impressed' FDA panel unanimously recommends GSK shingles vaccine

A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

Sep 13 2017

UPDATE 2-'Impressed' FDA panel unanimously recommends GSK shingles vaccine

Sept 13 A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

Sep 13 2017

BRIEF-Agenus Inc Q2 loss per share $0.32

* Agenus reports second quarter 2017 financial results and provides corporate update

Aug 03 2017

BRIEF-AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

* AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

Jun 05 2017

BRIEF-Agenus Q1 loss per share $0.18

* Agenus reports first quarter 2017 financial results and provides corporate update

May 04 2017

BRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

* Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

Apr 20 2017

BRIEF-Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

* Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

Apr 05 2017

BRIEF-Agenus says plans to close Basel site, combine key functions to Cambridge, UK and Lexington, MA facilities

* Agenus restructures business to sharpen focus on clinical development of cancer therapies

Mar 30 2017

Earnings vs. Estimates